The Global Carotid Artery Disease Market is expected to register a CAGR of 4.1% to reach USD 11,621.6 million till 2023.

Market Dynamics

Carotid artery disease is a condition in which plaques are developed in the arteries that supply blood to the brain, which often lead to strokes. The prominent factors that drive the market growth are increasing geriatric population, increasing adoption of an unhealthy lifestyle, and the popularity of over-the-counter (OTD) drugs. However, the high cost of diagnostics and surgeries and stringent government regulations for the carotid artery disease are likely to restrain market growth over the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6301

Carotid arteries are blood vessels in the neck that supply oxygen-rich blood to the brain. These vessels could get blocked by plaque, a fatty substance consisting of cholesterol, calcium, and other materials. Medication helps to reduce plaque build-up in carotid arteries and blood vessels throughout the body. Ardent efforts by manufacturers of therapeutic drugs for the treatment of carotid artery disease have aided the growth of the global carotid artery disease market. Medications often prescribed for carotid artery disease are antiplatelet medications, anticoagulant medications, tissue plasminogen activator (tPA). The most commonly used anti-platelet medication is aspirin. Other drugs include clopidogrel (Plavix) and dipyridamole (Persantine), which may be prescribed alone or in combination with aspirin to reduce the risk of stroke. This factor is expected to lead to the growth of the global carotid artery disease market and may even increase the revenue-generation ability of market players. The current first line of treatment for carotid artery disease includes anti-platelets medication and tissue plasminogen activator (tPA). The increasing demand for over-the-counter drugs by the patient population is boosting the growth of the market.

Segmentation

The global carotid artery disease market, diagnosis & treatment, has been segmented into diagnosis and treatment. Based on treatment, the market has been further divided into medications and surgical procedures. The medications segment has been sub-segmented into cholesterol-lowering statins, antiplatelet drugs, antihypertensive drugs. The surgical procedures segment has been further divided into carotid endarterectomy, carotid artery angioplasty & stenting, and carotid artery bypass.

Based on end user, the carotid artery disease market has been categorized as hospital & clinics, ambulatory surgical centers, pharmacies, and others.

Regional Analysis

The global carotid artery disease market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas accounted for the largest share in the global carotid artery disease market owing to the rising prevalence of chronic diseases, increasing levels of certain fats and cholesterol in the blood, and stringency of government regulations for drug development. According to the 2014 Surgeon General’s Report on smoking and health, it was estimated that 4,00,000 patients aged 70 years and older in the US suffered from asymptomatic carotid artery stenosis.

The European market was the second largest in 2017 in terms of market share. Factors such as growth in the biopharmaceutical sector, increasing government funding to promote research for the prevention of chronic diseases, the presence of developed economies, high per capita disposable incomes, and increased healthcare spending by consumers are driving the growth of the market in this region. According to the World Diabetes Foundation Organization, the number of people estimated to be suffering from diabetes in 2015 was 59.8 million. The increasing cases of diabetes are likely to drive the carotid artery disease market.

In 2017, Asia-Pacific was the third-largest in the global carotid artery disease market owing to a large number of research organizations, low manufacturing and labor cost, development of new infrastructure to support the healthcare industry, and increasing investments by major players. According to the India Brand Equity Foundation, India is becoming a leader in clinical trials, and contract research and manufacturing activities as the cost of drug production in the country are ~33% lower than that of the US. All these factors are likely to contribute to the fastest growth of the Asia-Pacific region during the forecast period.

Key Players

The prominent players in the global carotid artery disease market are W. L. Gore & Associates, Inc., Becton, Dickinson and Company, Terumo Corporation, Hitachi, Ltd, Silk Road Medical, Inc., Abbott, Medtronic, Stryker Corporation, Cardinal Health, and Boston Scientific Corporation.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/carotid-artery-disease-market-6301